Tuesday, November 20, 2007

Piper Jaffray Adds Acorda Therapeutics (ACOR) to Alpha List

Piper Jaffray Adds Acorda Therapeutics (ACOR) to Alpha List
StreetInsider.com (subscription) - Birmingham,MI,USA
Its lead product candidate, Fampridine-SR, has completed a positive Phase III clinical trial for the improvement of walking ability in people with MS.
See all stories on this topic

Most medical studies useless -- celebrated prof
Edmonton Journal - Edmonton,Alberta,Canada
Pearson hopes such research eventually could be applied to restore motor activity for people who have suffered spinal cord injuries. ...
See all stories on this topic

Most medical studies useless -- celebrated prof

'Hugely wasteful' of research resources, says new inductee to Royal Society of Canada
Ron Chalmers, The Edmonton Journal
Published: Monday, November 19

Less than one per cent of published biomedical research is both scientifically valid and clinically useful, says a scientist inducted into the Royal Society of Canada at a weekend ceremony at the Winspear Centre.

"This is a tragedy for many people with preventable or treatable health problems, hugely wasteful, and a

serious challenge to the concept of professionalism and self-regulation of health practitioners," Brian Haynes, a professor of clinical epidemiology and biostatistics at McMaster University, has written.

He was recognized for his pioneering work on evidence-based medicine at a ceremony that honoured 80 scholars, including 13 from the University of Alberta.

"The purpose of evidence-based medicine is to contribute to medical practice," Haynes told The Journal. Unfortunately, new research often appears justified more by its continuation of old research than by new evidence, he said.

"Science is incremental," Haynes said. Much of it merely assumes the validity of existing work -- rather than questioning it.

Most medical research has no immediate practical application, and working physicians cannot easily discover the useful studies because "about two million articles per year are published in biomedical literature," Haynes said.

He said his job is to "help doctors find that therapeutic needle in the information haystack."

Keir Pearson, a U of A professor of physiology who also was inducted, discussed his research on the neurobio-

logy of locomotion in a Royal Society public conference.

"There is a big effort now to create walking machines," which could be helped by research on the complex movements of cats, insects and fish, he said.

Pearson hopes such research eventually could be applied to restore motor activity for people who have suffered spinal cord injuries.

The Royal Society of Canada was founded in 1882 to encourage scholarship in science and the humanities.

rchalmers@thejournal.canwest.com

http://www.canada.com/edmontonjournal/news/cityplus/story.html?id=5006ac0c-4caf-4ecd-9d79-d1ac7a25b804&k=18708

Stem cell therapy shows promise, problems
Danbury News Times - Danbury,CT,USA
But she also acknowledged great potential for using stem cells to treat any number of diseases, including Type 1 diabetes, multiple sclerosis and ...
See all stories on this topic

• UCI center trades points with patients
Daily Pilot - Costa Mesa,CA,USA
Multiple sclerosis patients tour UCI's stem cell research center, where scientists say they are approaching breakthroughs they hope could save lives one day ...
See all stories on this topic

Minocycline May Have A Negative Effect In Some Neurological Conditions
New research published in the journal The Lancet Neurology has shown that the drug minocycline may have a harmful effect in people with Amyotrophic lateral sclerosis (ALS) according to one of the first randomised trials in people with a neurological disorder.
19 Nov 2007

Further Evidence To Link EBV Virus Infection With MS, UK
New research published in The Journal of Experimental Medicine has provided more evidence that a common human virus called Epstein Barr Virus (EBV) plays an important role in the development of MS.
19 Nov 2007

Elan "add"
newratings.com - Westerburg,Germany
An FDA advisory committee in the US has recommended the approval of Tysabri in Crohn's Disease and a decision is expected by January 13, ...
See all stories on this topic

EU commission recommends against Tysabri in Crohn's Mass High Tech ...
Bizjournals.com - Charlotte,NC,USA
PLC permission to market their drug called Tysabri for Crohn's disease, according to the companies. Cambridge-based Biogen and Ireland's Elan report the ...
See all stories on this topic

Breakthrough Drug for Debilitating Disease
Scoop.co.nz - New Zealand
Dr Ernest Willoughby, a neurologist at Auckland City Hospital, is in charge of a trial of Tysabri in Auckland, involving five patients with MS. ...
See all stories on this topic

Biogen, Elan Get Negative Drug Opinion
Houston Chronicle - United States
2007 AP NEW YORK — Elan Corporation Plc and Biogen Idec Inc. said Friday a European advisory committee recommended against approving the drug Tysabri for ...
See all stories on this topic

Elan's Tysabri suffers European setback
Irish Independent - Dublin,Ireland
The decision on Tysabri (natalizumab) will now be referred to the European Commission, the companies said in a statement. The decision was made by the ...
See all stories on this topic

Biogen drug gets negative opinion from European regulators
Bizjournals.com - Charlotte,NC,USA
Tysabri is already approved in Europe, as well as in the United States, as a treatment of multiple sclerosis. The companies wanted approval from the ...
See all stories on this topic

0 Comments:

Post a Comment

Links to this post:

Create a Link

<< Home